REDUCING PAYER UNCERTAINTY BY PREDICTING DISEASE OUTCOMES AND IDENTIFYING THE RIGHT PATIENT- FACT OR FANTASY?
Author(s)
Mark Ratcliffe, PhD, Chief Executive Officer, PHMR Ltd, London, United Kingdom; Peter Lindgren, Research Director, The Swedish Institute for Health Economics (IHE),; Pauline Hernandez, Patient at Inflammatory Bowel Disease,; Peter Clark, National Clinical Lead for Chemotherapy, NHS England,; Nicky Liebermann, Head of Medicine Community Division, Clalit Health Services,; Panos Kanavos, Associate Professor in International Health Policy, London School of Economics and Political Science,
Presentation Documents
Key stakeholders (payers, providers, and patients) contribute to data capacity as a way of implementing an agreement on a common target for disease modification. However, while academia and pharmaceutical companies contribute to predictive tools such as algorithms and pharma support absorbs decision risks.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Code
S5
Topic
Economic Evaluation